leisure time -WSS

leisure time

author：fashion 2025-10-01 15:29:48 - browse：6972

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Advances in CAR

entertainment

WSS

Weighted lottery helped low

Diverse clinical trials: Why aren’t we there yet?

Listen: Biogen's potential pivot, & Illumina's next chapter

Generate Biomedicines machine learning biotech raises $273M

Crinetics acromegaly drug succeeds in late

Food makers tried to stack nutrition panel with preferred experts

entertainment

leisure time

explore

State Dept. review finds Biden bears some blame for Afghanistan failures

WATCH: Why do bright lights make us see spots?

At least 13 dead in Texas as scorching temps continue

New Covid vaccine is recommended for everyone 6 months or older

Dobbs anniversary: the lost opportunity of abortion as health care

White House touts steps to stem shortages of cancer treatments

BioMarin wins approval for gene therapy to treat hemophilia A

NIH nominee Bertagnolli will get October confirmation hearing

Peter Hotez and the public health issue of online harassment

Snackable artificial intelligence, expert AI, and the pharma industry

leisure time

Weighted lottery helped low

How medical schools plan to diversify without affirmative action

How to protect patients from sexual assault

IRA could hurt research into orphan drugs for rare diseases

White House touts steps to stem shortages of cancer treatments

Telehealth for opioid use disorder is lifesaving

entertainment

explore

entertainment

entertainment